Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

This study is testing a newer form of the chemotherapy drug irinotecan (delivered inside tiny fat bubbles called liposomes) as a first-line treatment for colorectal cancer that has spread and cannot be surgically removed. Researchers want to see if this approach works better than standard treatments for people with specific tumor characteristics. **You may be eligible if...** - You are between 18 and 85 years old - You have been diagnosed with colorectal cancer that has spread and cannot be operated on - Your tumor has been tested and found to have RAS or BRAF mutations, or the cancer started on the right side of the colon - Your cancer has not yet received any systemic (whole-body) treatment - You are generally active and able to care for yourself (good performance status) - Your blood counts, liver, and kidney function are within acceptable ranges **You may NOT be eligible if...** - The cancer has spread to your brain or spinal cord - You have previously received irinotecan or bevacizumab - You had surgery or cancer treatment in the last 4 weeks - You have serious bowel problems such as obstruction or perforation - You have interstitial lung disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.